NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL
NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL
Shots:
- Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab
- BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method, supply of GMP clinical material, and CMC filing support with the NMPA
- Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global market, if approved in china